ITMCTR2200006048招募中未知
A single center, retrospective, randomized controlled trial of Pu Ping Qing Hua Fang vs Lian Hua Qing Wen in shortening the time of turning negative in novel coronavirus positive patients
适应症
试验速览
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional study
入排标准
- 年龄范围
- 18 至 90（—）
- 性别
- All
入选标准
- •1) Sign written informed consent before any study specific operation or treatment, aged 18-90 years, regardless of gender;
- •2) The patient was infected with novel coronavirus and confirmed by rtPCR;
- •3) The Eastern Cooperative Oncology Group (ECOG) performance score was 0 or 1.
- •4) After screening and examination, it is determined that it has sufficient baseline organ function and hematological function.
- •5) Must agree and comply with the visit plan of the study and other requirements specified in the protocol, including telephone follow-up.
排除标准
- •1) Pregnant or lactating women with ECOG score greater = grade 2;
- •2) There is untreated tumor central nervous system (CNS) metastasis. If the imaging examination shows that there is no new metastasis or metastasis progression after at least 4 weeks after the treatment of CNS metastasis, the subject fluid is allowed to be included in this study. CNS imaging examination during screening is not necessary, but only for people with clinical indications.
- •3) Patients who had undergone major surgery within 28 days before randomization in this study.
- •4) Uncontrolled active bleeding or bleeding tendency.
- •5) Clinically significant gastrointestinal abnormalities that may affect the absorption of the study drug or even increase the risk of bleeding or perforation, including any previous history of gastrointestinal perforation.
- •6) Other malignant tumors requiring treatment in the past 3 years.
- •7) Poorly controlled hypertension is defined as systolic blood pressure = 160 or diastolic blood pressure = 100 mmHg. Allow the use of antihypertensive drugs and rescreening.
- •8) Any one or more of the following medical history within 6 months before randomization: symptomatic peripheral vascular disease; Coronary artery bypass grafting; Myocardial infarction or unstable angina pectoris; Cardiac angioplasty or stent implantation; Cerebrovascular accidents, including transient ischemic attack.
- •9) New York Heart Association class III or IV congestive heart failure.
- •10) There are uncontrolled concurrent diseases, and these factors will affect the subjects' compliance with the relevant requirements of this study.
研究者
相似试验
已完成
不适用
Preservation technique of ruptured anterior cruciate ligament (ACL)Anterior cruciate ligament (ACL) injuryInjury, Occupational Diseases, PoisoningSprain and strain involving (anterior)(posterior) cruciate ligament of kneeISRCTN89368687Swiss National Insurance Association (SUVA) (Switzerland)100
尚未招募
不适用
A prospective, single-center, randomized, controlled, evaluator-blinded(independent evaluator), feasibility clinical trial to evaluate efficacy and safety of Pulsed High-Intensity Focused Ultrasound therapy ‘IMD10’ with neoadjuvant in pancreatic cancerKCT0008066IMGT30
招募中
不适用
Prospective, randomized controlled, single center study evaluating additional respiration therapy with a PEP trainer to prevent pneumonia in patients with higher neutropenic risk under chemotherapeutic treatment of an acute myeloic leukemiaC92J18Myeloid leukaemiaPneumonia, organism unspecifiedDRKS00019842Vivantes Klinikum Neukölln - Hämatologie, Onkologie und Palliativmedizin100
已完成
不适用
Comparison of two devices for breathing support in newborn babiesPremature birthTransient tachypnea of the newbornACTRN12619000535178Fisher & Paykel Healthcare10
已完成
3 期
Magnesium in Aneurysmal Subarachnoid HaemorrhageSubarachnoid HaemorrhageBlood - Other neurological disordersBlood - Other blood disordersACTRN12605000058673Pharmalab162